Back to top
more

Medpace (MEDP)

(Delayed Data from NSDQ)

$319.56 USD

319.56
307,956

+5.34 (1.70%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $319.71 +0.15 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical Services

Better trading starts here.

Zacks News

Veracyte (VCYT) Up 6% Since Last Earnings: Will it Continue?

Investors are optimistic about Veracyte (VCYT) led by strength in the testing business and upbeat guidance.

Here's Why You Should Hold on to Abbott (ABT) Stock for Now

Abbott's (ABT) share recovery in the Nutrition business buoys optimism.

IDEXX (IDXX) Witnesses Rising Expenses, Currency Issues

IDEXX (IDXX) is being hurt by geopolitical instability, including the current war in Ukraine, which has affected supply chain operations globally.

Here's Why You Should Hold Surmodics (SRDX) Stock for Now

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Here's Why Investors Should Buy ResMed (RMD) Stock Now

Investors are optimistic about ResMed's (RMD) potential in digital health and expansion in the international market.

Boston Scientific (BSX) mCRM System Study Outcome Favorable

Boston Scientific (BSX) mCRM System is designed to communicate wirelessly and coordinate painless intracardiac anti-tachycardia pacing (ATP) therapy.

Medtronic (MDT) Reports Favorable SPHERE Per-AF Trial Outcome

Medtronic's (MDT) Affera Mapping and Ablation System with Sphere-9 Catheter achieves endpoints for safety and efficacy for the treatment of AFib.

Haemonetics' (HAE) Hospital & Plasma Segments, Innovation Aid

Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.

Maravai (MRVI) Advances in RNA Research With New Collaboration

Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies.

Haemonetics (HAE) Stock Up 10.9% YTD: Will the Rally Continue?

Investors are optimistic about Haemonetics (HAE) led by its strategic focus on establishing leading positions in high-growth markets to generate solid financial returns.

Tandem Diabetes (TNDM) Hits 52-Week High: What's Driving It?

Tandem Diabetes (TNDM) outperforms the industry, owing to its impressive series of product launches and an impressive quarterly performance.

Tirthankar Chakraborty headshot

4 Best Momentum Stocks Worth a Buy Using Driehaus Strategy

Stocks like Wingstop (WING), Medpace (MEDP), Comfort Systems USA (FIX) and HCI Group (HCI) have been selected as the momentum picks for the day using the Driehaus strategy.

Butterfly Network (BFLY) Unveils iQ+ Bladder Ultrasound Scanner

Butterfly Network (BFLY) uses proprietary Ultrasound-on-Chip technology to streamline the bladder scanning process.

Align Technology (ALGN) Gains From Innovation, Global Expansion

In the United States, Align Technology (ALGN) is focused on reaching young adults as well as teens and their parents through famous athletes, influencers and fashion designers.

Prestige Consumer (PBH) Q4 Earnings Miss, Operating Margin Falls

Prestige Consumer's (PBH) Q4 business suffers from supply chain pressure that impacts its ability to fulfill retailer orders.

Labcorp (LH) to Assess Preeclampsia Risk With New Test

Labcorp's (LH) new first-trimester test is the latest addition to its dedication to improving women's health.

Profound Medical (PROF) Adds AI to Prostate Cancer Treatment

Profound Medical's (PROF) Contouring Assistant integrates AI into prostate cancer procedures, thereby streamlining the treatment planning process and enhancing both efficiency and precision.

Thermo Fisher (TMO) Unveils New Extended Blood Genotyping Array

Thermo Fisher's (TMO) new Applied Biosystems Axiom BloodGenomiX Array and Software provide a high-throughput solution for more precise blood matching research.

Here's Why Investors Should Retain QIAGEN (QGEN) Stock Now

QIAGEN's (QGEN) solid potential in the NGS platform buoys optimism for investors.

Here's Why You Should Retain Henry Schein (HSIC) Stock for Now

Investors are optimistic about Henry Schein (HSIC), owing to strategic acquisitions and potential in Henry Schein One.

Centene (CNC) to Continue Serving Kansas' Medicaid Members

Centene's (CNC) subsidiary wins contract from the Kansas Department of Administration to continue providing comprehensive healthcare services to the KanCare program's members.

Here's Why You Should Buy Align Technology (ALGN) Stock Now

Investors are optimistic about Align Technology (ALGN) led by expansion in new geographies and upbeat guidance.

QIAGEN's (QGEN) QCI Interpret Gets European IVDR Certification

QIAGEN's (QGEN) Clinical Insight Interpret is the first NGS interpretation platform approved by IVDR for use in cancer and hereditary applications.

Here's Why You Should Retain Zimmer Biomet (ZBH) Stock for Now

Strong procedure recovery and progress on the four-pillar strategy bode well for Zimmer Biomet (ZBH).

Senseonics' (SENS) Deal With Mercy to Drive Eversense CGM Sales

Senseonics Holdings (SENS) collaborates with Mercy to bring its Eversense CGM to a healthcare system that is likely to drive its adoption.